135 related articles for article (PubMed ID: 11939684)
21. A comparison between the use of recombinant hirudin and heparin during hemodialysis.
van Wyk V; Badenhorst PN; Luus HG; Kotzé HF
Kidney Int; 1995 Oct; 48(4):1338-43. PubMed ID: 8569097
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
23. Treatment of hirudin overdosage in a dialysis patient with heparin-induced thrombocytopenia with mixed hemodialysis and hemofiltration treatment.
Mon C; Moreno G; Ortiz M; Diaz R; Herrero JC; Oliet A; Rodriguez I; Ortega O; Gallar P; Vigil A
Clin Nephrol; 2006 Oct; 66(4):302-5. PubMed ID: 17063999
[TBL] [Abstract][Full Text] [Related]
24. Lepirudin is a safe and effective anticoagulant for patients with heparin-associated antiplatelet antibodies.
Mudaliar JH; Liem TK; Nichols WK; Spadone DP; Silver D
J Vasc Surg; 2001 Jul; 34(1):17-20. PubMed ID: 11436069
[TBL] [Abstract][Full Text] [Related]
25. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial.
Neuhaus KL; Molhoek GP; Zeymer U; Tebbe U; Wegscheider K; Schröder R; Camez A; Laarman GJ; Grollier GM; Lok DJ; Kuckuck H; Lazarus P
J Am Coll Cardiol; 1999 Oct; 34(4):966-73. PubMed ID: 10520777
[TBL] [Abstract][Full Text] [Related]
26. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.
Greinacher A
Expert Rev Cardiovasc Ther; 2004 May; 2(3):339-57. PubMed ID: 15151481
[TBL] [Abstract][Full Text] [Related]
27. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method.
Fenyvesi T; Jörg I; Harenberg J
Pathophysiol Haemost Thromb; 2002; 32(4):174-9. PubMed ID: 12759518
[TBL] [Abstract][Full Text] [Related]
28. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.
Greinacher A; Lubenow N; Eichler P
Circulation; 2003 Oct; 108(17):2062-5. PubMed ID: 14568897
[TBL] [Abstract][Full Text] [Related]
29. Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass.
Fabrizio MC
J Extra Corpor Technol; 2001 May; 33(2):117-25. PubMed ID: 11467439
[TBL] [Abstract][Full Text] [Related]
30. Excessive anticoagulation and anaphylactic reaction after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia.
Badger NO; Butler K; Hallman LC
Pharmacotherapy; 2004 Dec; 24(12):1800-3. PubMed ID: 15585446
[TBL] [Abstract][Full Text] [Related]
31. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban.
Gray E; Harenberg J;
J Thromb Haemost; 2005 Sep; 3(9):2096-7. PubMed ID: 16102117
[No Abstract] [Full Text] [Related]
32. Lepirudin anticoagulation for heparin-induced thrombocytopenia.
Deitcher SR; Topoulos AP; Bartholomew JR; Kichuk-Chrisant MR
J Pediatr; 2002 Feb; 140(2):264-6. PubMed ID: 11865285
[TBL] [Abstract][Full Text] [Related]
33. Sites of elimination and pharmacokinetics of recombinant [131I]lepirudin in baboons.
Meiring SM; Lötter MG; Badenhorst PN; Bucha E; Nowak G; Kotzé HF
J Pharm Sci; 1999 May; 88(5):523-9. PubMed ID: 10229643
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
[TBL] [Abstract][Full Text] [Related]
35. Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin.
Oh JJ; Akers WS; Lewis D; Ramaiah C; Flynn JD
Pharmacotherapy; 2006 Apr; 26(4):569-577. PubMed ID: 16553518
[TBL] [Abstract][Full Text] [Related]
36. Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease.
Linnemann B; Greinacher A; Lindhoff-Last E
Vasa; 2010 Feb; 39(1):103-7. PubMed ID: 20186683
[TBL] [Abstract][Full Text] [Related]
37. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.
Lancet; 1999 Feb; 353(9151):429-38. PubMed ID: 9989712
[TBL] [Abstract][Full Text] [Related]
38. The use of lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia during major vascular surgery.
Sun Y; Greilich PE; Wilson SI; Jackson MR; Whitten CW
Anesth Analg; 2001 Feb; 92(2):344-6. PubMed ID: 11159229
[TBL] [Abstract][Full Text] [Related]
39. Monitoring of anticoagulant effects of direct thrombin inhibitors.
Fenyvesi T; Jörg I; Harenberg J
Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
[TBL] [Abstract][Full Text] [Related]
40. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.
Greinacher A; Völpel H; Janssens U; Hach-Wunderle V; Kemkes-Matthes B; Eichler P; Mueller-Velten HG; Pötzsch B
Circulation; 1999 Jan 5-12; 99(1):73-80. PubMed ID: 9884382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
